Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Santen Pharmaceutical (4536 JP): Inventory Adjustment Impact Q1, RC28-E BLA Acceptance Augurs Well

Santen Pharmaceutical (4536 JP): Strong H1 Performance; FY24 Guidance Raise; Rich Pipeline

Santen Pharmaceutical (4536 JP): Subdued H1 Performance; FY25 Guidance Reiterated; Robust Pipeline

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/santen-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:8602:1" rel="noopener">Santen Pharmaceutical (4536 JP)</a> witnessed revenue drop with profits also declining in H1FY26. Sequential quarterly improvement a positive. EMEA and Asia grow driving the overseas business rise.</li>
<li>Company reiterated FY26 guidance where revenue is projected at ¥294B (down 2% YoY) and core operating profit at ¥54B (down 9% YoY). H2FY26 expected to be strong.</li>
<li>Regular drug development, consistent approvals for new indications coupled with licensing deals and its market leadership position will help Santen to see through the sluggishness.</li>
</ul>



Santen Pharmaceutical (4536 JP) witnessed revenue drop with profits also declining in H1FY26. Sequential quarterly improvement a positive. EMEA and Asia grow driving the overseas business rise.
Company reiterated FY26 guidance where revenue is projected at ¥294B (down 2% YoY) and core operating profit at ¥54B (down 9% YoY). H2FY26 expected to be strong.
Regular drug development, consistent approvals for new indications coupled with licensing deals and its market leadership position will help Santen to see through the sluggishness.


Santen Pharmaceutical (4536 JP): Sequential Improvement, Guidance Reiterated, Better H2 Anticipated